New diagnostic and prognostic tools in bladder cancer.
Many efforts have been made to increase the detection rates and to predict the outcome of bladder cancer. Although to date cystoscopy remains the gold standard method for the detection of new or recurrent bladder cancer, its limitations were emphasized by the results of studies using fluorescence endoscopy that showed an increased detection rate and decreased recurrence after tumor resection. Urine cytology has high specificity and is used routinely as an adjunct to cystoscopy to detect invisible tumors. However, to improve on the low sensitivity of urine cytology, a number of marker tests have been developed. Optimal diagnostic accuracy appears to result from the synergistic combination of cytological markers with urine cytology. The evaluation of new and previously reported markers remains a very active field, but is still limited to inconclusive studies. Tissue and DNA microarrays represent a technological step forward for the analysis of a large number of markers and cohorts of patients that will be required definitively to establish the clinical utility of prognostic tests.
Tiguert
Rabi
R
Laval University Cancer Research Center, CHUQ l'Hôtel-Dieu de Québec, Québec, Canada.
Fradet
Yves
Y
D014408:Biomarkers, Tumor / Q000032:analysis* / Q000652:urine; D003558:Cystoscopy / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D011379:Prognosis; D012680:Sensitivity and Specificity; D016482:Urinalysis; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000628:therapy / Q000652:urine
D014408:Biomarkers, Tumor